| abstract |
The present invention relates to aryl triazole derivatives of formula I having antitumor activity via molecular chaperone heat shock protein 90 (Hsp90) inhibitors as one possible biological target. The present invention includes the use of such compounds and pharmaceutical compositions containing such compounds as medicaments for cancer diseases and other diseases to which Hsp90 inhibitors are responsive. |